SEC Comment Letter 0000000000-24-010526 to Indaptus Therapeutics, Inc. (INDP)
Indaptus Therapeutics, Inc.
Date: Sept. 17, 2024 · CIK: 0001857044 · Accession: 0000000000-24-010526
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-282069
Letter
September 17, 2024 Jeffrey Meckler Chief Executive Officer Indaptus Therapeutics, Inc. 3 Columbus Circle 15th Floor New York, NY 10019 Re:Indaptus Therapeutics, Inc. Registration Statement on Form S-1 Filed September 12, 2024 File No. 333-282069 Dear Jeffrey Meckler: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Lisa Martin
Show Raw Text
September 17, 2024
Jeffrey Meckler
Chief Executive Officer
Indaptus Therapeutics, Inc.
3 Columbus Circle
15th Floor
New York, NY 10019
Re:Indaptus Therapeutics, Inc.
Registration Statement on Form S-1
Filed September 12, 2024
File No. 333-282069
Dear Jeffrey Meckler:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Lisa Martin